Can Atorvastatin reduce lipid abnormalities caused by long-term immunosuppressive therapy, and what are the considerations for managing transplant recipients?
Sahil KapoorExplorer
Can Atorvastatin reduce lipid abnormalities caused by long-term immunosuppressive therapy?
Share
Atorvastatin can mitigate lipid imbalances from long-term immunosuppressive therapy in transplant recipients. Regular monitoring for drug interactions and liver function is crucial.
Atorvastatin is effective in managing dyslipidemia in transplant patients on immunosuppressants, but requires careful monitoring for potential interactions, particularly with calcineurin inhibitors.